A workplace flu program has costs that can be counted and possible benefits that are harder to attribute. A responsible business case keeps those two things separate. It can explain why convenient vaccination access is worth offering without promising that every dollar spent will produce a particular reduction in sick leave.
Return on investment, or ROI, is a calculation built from assumptions. It becomes misleading when uncertain estimates are presented as measured savings. For a small employer, the most defensible first-year evaluation may focus on access, participation and delivery quality, with any financial scenario clearly labelled as illustrative.
Define the decision before building a spreadsheet
Decide what the program is intended to achieve. Possible objectives include making vaccination easier to access, supporting staff who work shifts or integrating vaccination into an occupational health plan. Each objective needs a different measure. The number attending a clinic tells you about use of the service, not how many infections were prevented.
Keep the employer's objectives separate from individual clinical recommendations. Some workers have particular occupational exposures, addressed in the Australian Immunisation Handbook. Others may have personal risk factors that should remain private. An economic model should not become a mechanism for managers to judge an employee's medical decision or demand details that are unnecessary for program evaluation.
Count the full cost consistently
Start with the provider quotation and include any agreed venue, travel or minimum-session charges. Then consider staff time spent organising the clinic and attending it. If you count paid attendance time as a cost, use the same convention in every scenario. Otherwise comparisons between an on-site clinic and an external option can be distorted.
Separate one-off setup work from costs that recur each year. Record cancellations and unused appointment capacity without treating every empty slot as a clinical failure. A budget should also identify who bears each cost. Employer expenditure, employee out-of-pocket costs and public funding are different perspectives and should not be mixed together without explanation.
Understand what influenza vaccination can address
Influenza vaccination targets influenza, not every cause of cough, fever or absence. Effectiveness varies by season, population and outcome. A reduction in all winter sick leave cannot be assumed from an influenza vaccine effectiveness estimate. Other infections, caring responsibilities and non-infectious illness can all contribute to the employer's absence total.
Likewise, preventing a medically attended infection and preventing a day away from work are different endpoints. A study of one does not automatically provide the other. If a business case uses published research, check the population, season, outcome and comparison group. Explain why the evidence is relevant to your workforce and where it is only an approximation.
Use an explicitly hypothetical break-even example
Suppose, purely for illustration, a program costs an employer $2,400 and the employer values one avoided absence day at $300. Dividing $2,400 by $300 gives eight days. That is the number of attributable avoided days required to break even under those assumptions. It is not evidence that the program will prevent eight days of absence.
The result changes if either input changes. It also depends on what the daily value represents. A wage paid during absence is not always an additional cash saving when an employee attends work; replacement costs and lost output are different concepts. Label the model's perspective and avoid adding several overlapping measures of the same lost day.
Show uncertainty instead of hiding it
A useful scenario analysis might vary program cost, participation and the assumed value of an avoided day. If you include an estimated number of prevented illnesses, show where that estimate comes from and how uncertain it is. Include a scenario with no measurable absence saving. That is an honest possibility, especially in a small workforce or a mild season.
Do not select only the most favourable published estimate or apply a percentage to the whole annual absence bill. Present the range as a planning tool, not a forecast with scientific authority. Decision makers can then see whether the program remains acceptable on access and staff-support grounds when financial benefits are uncertain.
Evaluate outcomes without claiming causation
Comparing this winter with last winter can be informative, but many things may have changed: circulating infections, staffing, remote work, leave policies and reporting habits. A fall in absence after the clinic does not prove that the clinic caused it. A rise does not prove that vaccination was ineffective either.
For routine review, use consistently defined aggregate measures and describe the limitations. Consider participation by shift or location only where groups are large enough to protect privacy. Do not link clinical screening responses to personnel performance data. A credible report can state that the program reached a particular proportion of eligible invitees without claiming a medical outcome it did not measure.
Make the next decision from the whole picture
Review whether the clinic ran smoothly, whether workers could attend and whether the communication answered their questions. Ask what prevented participation and whether an alternative arrangement would improve access. These findings can guide a better service even when a financial ROI cannot be estimated reliably.
A balanced recommendation should state the known cost, the observed service results and the assumptions behind any economic scenario. Avoid slogans about guaranteed productivity or a fixed number of dollars returned. If a rigorous health-economic evaluation is needed, obtain appropriate expertise and a suitable study design. For most small employers, a transparent modest business case is more useful than an impressive-looking number built on unsupported certainty.
Sources & further reading
General information only. This article is educational and is not a substitute for personal medical advice. Your immuniser will confirm eligibility and contraindications on the day.
Ask your pharmacist or GP about suitability, benefits, risks and alternatives before making a treatment decision.